Determinants of reinfection with SARS-CoV-2 Omicron variant
- PMID: 37302660
- PMCID: PMC10256591
- DOI: 10.1016/j.jinf.2023.06.002
Determinants of reinfection with SARS-CoV-2 Omicron variant
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures


Comment on
-
Neutralizing antibodies against Omicron BA.4/5 after COVID-19 vaccination in SARS-CoV-2 experienced versus naïve individuals in the general population.J Infect. 2023 Mar;86(3):256-308. doi: 10.1016/j.jinf.2022.12.029. Epub 2023 Jan 1. J Infect. 2023. PMID: 36599404 Free PMC article. No abstract available.
References
-
- Camacho J., Zulaica J., Gimenez E., Rusu L., Velandia-Alvarez S., Albert E., et al. Neutralizing antibodies against Omicron BA.4/5 after COVID-19 vaccination in SARS-CoV-2 experienced versus naive individuals in the general population. J Infect. 2023;86(3):256–308. doi: 10.1016/j.jinf.2022.12.029. - DOI - PMC - PubMed
-
- Bobrovitz N., Ware H., Ma X., Li Z., Hosseini R., Cao C., et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;23(5):556–567. doi: 10.1016/S1473-3099(22)00801-5. - DOI - PMC - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous